Clay Siegall is one of the prominent figures in the biotech industry. He is known for contributing to the creation of Seattle Genetics, a biotech company that strives to develop cancer drugs. Siegall usually pays close attention to emerging trends in the industry. He believes that these trends would advance cancer drug research and development.
Besides his leadership role in Seattle Genetics, Siegall is also a writer for Xcomomy, a blog focusing on biotechnology advances. In one of his recent articles, Clay Siegall shared his insights regarding the best five biotech innovations. He believes that these innovations would facilitate the development of treatments and drugs for diverse diseases.
The Top Five Biotech Innovations of this Decade
The first position is held by cancer therapies developed by Celgene and Roche/Genentech. Celgene is known for developing a drug known as lenalidomide. The drug has undergone numerous clinical trials before its approval. Roche and Genentech, biotech companies, also partnered in the development of trastuzumab, a cancer drug.
In the second position, Siegall mentioned HIV therapies that are prevalent these days. The therapies include tenofovir, emtricitabine, and efavirenz that have been developed by Gilead Sciences.
According to Clay Siegall, flu vaccines have also played a crucial role in preventing the spread of contagious diseases. Siegall is also optimistic about the most recent hepatitis C treatments like telaprivir created by Vertex Pharmaceuticals. Tumor vaccines like sipuleucel-T also made it to Siegall’s list of the most prevalent innovations in the biotechnology sector.
About Clay Siegall
Since Seattle Genetics’ inception in 1998, Clay Siegall has been serving as the firm’s CEO, directors’ board member, and president. His executive role at the company involves overseeing the firm’s clinical and preclinical research programs. Seattle’s flagship cancer drug is known as SGN-40. It is among other drugs developed by Seattle Genetics, in collaboration with Genetech, under Siegall’s tenure. It is also based on the antibody-drug conjugate (ADC) platform.
Siegall also held leadership roles in companies and research institutions like the National Cancer Institute and Bristol-Meyers Squibb Pharmaceutical Research Institute. He acquired his undergraduate zoology degree from the University of Maryland and his doctorate in genetics from the famed George Washington University.